Transforming Cancer Treatment

OncoNOx Products

OncoNOx is a BioPharmaceutical Company focused on designing novel NO-containing/releasing small molecules based on clinically validated chemical scaffolds. OncoNOx’s technology transforms marketed drugs into novel, proprietary molecules with potent anti-cancer properties and an improved therapeutic profile by covalent attachment of a nitric oxide (NO) moiety to the chemical structure.

The lead projects; OX1001 and OX27-NO have both been shown to be potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer. OX1001 also exhibits anti-viral activity and is in development for treatment of HIV and AIDS patients with or without HIV related cancer.